First Right. Merrimack shall have the first right, but not the obligation, to enforce the Licensed Antibody Program Patents against Infringement through [**] (“License-Competitive Infringement”). Merrimack shall reasonably consider Adimab’s comments on any such enforcement activities. Except as provided in subsection (d) or in Section 5.8, Merrimack shall bear all costs and expenses for enforcement under this Section 5.7(b)(i) (including the costs of Adimab’s cooperation as required under subsection (e)).
Appears in 2 contracts
Sources: Collaboration Agreement (Merrimack Pharmaceuticals Inc), Collaboration Agreement (Merrimack Pharmaceuticals Inc)